S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Tropion‑Breast O2: Dato‑DXD first‑line results
Heather McArthur summarizes Tropion‑Breast O2 PFS benefit for Dato‑DXD versus chemotherapy and subgroup consistency.
Play episode from 15:55
Transcript
